Across 37 studies (4 randomized trials, 33 observational; 4,692 patients), adding an intestinal bypass to sleeve gastrectomy produced procedure-specific results. SADI-S (single-anastomosis duodeno-ileal bypass) and SASI (sleeve with single-anastomosis ileal bypass) delivered significantly greater weight loss and type 2 diabetes remission than sleeve alone. SG-JJB (jejunojejunal bypass) gave modest weight-loss gains, while SG-DJB (duodenojejunal bypass) showed modestly higher major complication rates without a clear efficacy advantage. Median follow-up was only 12 months, and certainty of evidence was mostly low to very low. The logic is sound: sleeve gastrectomy often leaves patients with weight regain, reflux, or incomplete diabetes remission, and adding a malabsorptive or hormonal bypass component targets those gaps. The signal for SADI-S and SASI fits earlier single-arm data and the mechanism, since greater nutrient diversion should drive larger metabolic effects. But the safety picture is the weak point. The authors concede that the null finding on major complications reflects imprecise estimates that cannot rule out a meaningful increase in risk. Malabsorption also brings long-term concerns, including protein and micronutrient deficiencies, diarrhea, and revisional surgery, that a 12-month window cannot capture. With observational data dominating, this is hypothesis-generating rather than practice-changing. Anyone weighing metabolic surgery should read it as a reason to ask surgeons about procedure-specific outcomes and long-term nutritional follow-up, not as proof that more complex operations are better.